(P022) Effectiveness of Intensity-Modulated Radiation Therapy With Simultaneous Integrated Boost in Cervical Cancer Patients With Positron Emission Tomography (PET)-Positive Lymph Nodes
Intensity-modulated radiation therapy with simultaneous integrated boost to PET-positive nodes is well tolerated and provides good local control and OS in node-positive cervical cancer patients.
John W. Shumway, BA, Alfredo E. Echeverria, MD, Umang Patel, MD, Mark D. Bonnen, MD, Michelle S. Ludwig, MD, MPH, PhD; Baylor College of Medicine
PURPOSE: Evaluate the effectiveness of intensity-modulated radiation therapy (IMRT) with simultaneous integrated boost (SIB) in cervical cancer patients with positron emission tomography (PET)-positive lymph nodes. Although it is not a Radiation Therapy Oncology Group–recommended treatment modality, due to overall poor prognosis, we utilize this technology in this class of patients.
MATERIALS AND METHODS: Forty patients with pelvic node–positive cervical cancer (International Federation of Gynecologists and Obstetricians [FIGO] stage IB1–IVB) treated with definitive chemoradiation from 2013–2014 with IMRT were retrospectively analyzed. Patients were treated with IMRT, with the pelvis and uninvolved nodes receiving 1.8 Gy/day to 45–50.4 Gy and the PET-positive nodes treated at 2.07 Gy/day to 51.75–57.96 Gy, depending on bowel tolerance. Patients then received brachytherapy, followed by a boost, to bring positive nodes to 60–66 Gy. Full and empty bladder simulations and cone beam CT were utilized to optimize reproducibility.
RESULTS: Patients had a median of six PET-positive nodes. A total of 17 patients (43%) received full extended-field IMRT for PET-positive para-aortic nodes (up to T12), and 11 patients (28%) received partial extended-field IMRT for PET-positive common iliac nodes (up to L2). With a mean follow-up of 16 months, 15 patients (37%) had recurrent or persistent disease. Sites of recurrent/persistent disease were cervix (6 [15%]), regional nodes (6 [15%]), and distant (10 [26%]). The 2-year overall survival (OS) was 87% (standard error [SE], 0.6), and 2-year progression free survival (PFS) was 63% (SE, 0.9). Treatment was well tolerated; 15 patients (38%) experienced grade 2 gastrointestinal (GI) toxicity, and 1 patient (2%) experienced a grade 3 adverse GI event. With full extended-field IMRT, seven patients (18%) experienced grade 2 adverse GI events vs five patients (13%) with partial extended-field IMRT. Neither group experienced grade 3 adverse GI events.
CONCLUSIONS: IMRT with SIB to PET-positive nodes is well tolerated and provides good local control and OS in node-positive cervical cancer patients.
Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
